TD Cowen Insights

Recorded on 03/03/26 TD Cowen life science & diagnostic tools analyst Kyle Boucher speaks with Bio-Techne CEO Kim Kelderman at TD Cowen's 46th Annual Health Care Conference to discuss Bio-Techne's 50-year anniversary, innovation and portfolio evolution, and growth pillars ahead. Since 1976 Bio-Techne has offered a wide range of critical reagents, assays, and analytical tools for customers in diagnostic, pharma, biotech, and academic settings, and has created one of the most consumables-focused portfolios in life science tools. CEO Kelderman reflects on Bio-Techne's 50-year history, including the last 10 years where the portfolio has grown through several inorganic acquisitions addressing multiple high-growth verticals that have laid the foundation for the next leg of growth. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 03/01/26 TD Cowen senior biotech analyst Phil Nadeau speaks with Rhythm CEO David Meeker and CFO Hunter Smith at TD Cowen’s 46th Annual Health Care Conference to discuss Rhythm's strategic vision for establishing itself as the premier company in the orphan obesity space. Rhythm leverages the melanocortin pathway to address severe, early-onset obesity disorders, and its strategy is structured around three main pillars: genetic obesities, hypothalamic obesity (HO), and Prader-Willi syndrome. Building on the successful launch of Imcivree in Bardet-Biedl syndrome (BBS), Rhythm is now preparing for what may be its most significant launch to date: Imcivree for the treatment of hypothalamic obesity. Rhythm is optimistic that Imcivree will set a new standard of care for HO, significantly improve patient outcomes, and generate considerable value for shareholders. Beyond HO, Meeker and Smith outlined additional opportunities for Rhythm’s melanocortin-4 receptor (MC4R) agonists in other rare obesity disorders. These include ongoing investigations in various genetic obesity conditions as part of the Phase III EMANATE trial, as well as progress in Prader-Willi syndrome, where Imcivree demonstrated proof-of-concept efficacy in late 2025. To ensure the long-term success of the MC4R franchise, Rhythm is advancing a comprehensive life cycle management strategy, which includes the clinical development of next-generation MC4R agonists such as bivamelagon and RM-718. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 03/03/26 TD Cowen senior biotech analyst Ritu Baral speaks with Compass CEO Kabir Nath at TD Cowen’s 46th Annual Health Care Conference. Discussion focused on FDA’s current approach to psychedelic drug development, what it signals for the broader psychiatry landscape, and the evolving interventional psychiatry infrastructure in the community setting. Nath highlights a highly engaged and collaborative FDA Psychiatry Division, noting the agency's recent acceptance of 7-8 psychedelic therapy INDs, and its willingness to work constructively with sponsors despite relatively small datasets in early development. He highlights recent positive psychedelic clinical datasets as many traditional antidepressant approaches continue to fall short, including Compass’s successful Phase 2 and 3 TRD results across three standardized studies as evidence of the category’s clinical potential. The conversation also explores how the existing interventional psychiatry infrastructure in the community setting, shaped in part by the successful launch of Spravato, has transformed the field and lowered barriers for future commercial uptake of innovative psychedelic therapies. With 7200+ certified Spravato treatment sites now in place and increasing familiarity with REMS-based models, Nath emphasizes the importance of bringing forward additional options in the psychedelic space to address significant unmet need across MDD, TRD, and PTSD as psychiatry treatment paradigms continue to evolve. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.